Chandrashekar BS, et al. - In the present study, the researchers tested the safety and effectiveness of oral voriconazole in the management of recalcitrant and recurrent dermatophytosis. Clinically diagnosed and KOH positive cases of extensive, recurring, and resistant dermatophytosis were given a two-week course of Tab voriconazole, 800 mg on day one and 400 mg/day in two divided doses for the remaining 13 days. The study was completed by 40 patients. Voriconazole is a novel oral antifungal that can be used to treat recurrent and resistant dermatophytosis. It has a good efficacy and safety profile, with a very low recurrence rate. During the course of treatment, no side effects were observed.